
USD
+$0.00
(+0.00%
)At Close (As of Nov 3, 2025)
$63.97B
Market Cap
24.89
P/E Ratio
5.8
EPS
$179.46
52 Week High
$138.28
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $6.4B |
| Total Revenue | $9.3B |
| Cost Of Revenue | $2.9B |
| Costof Goods And Services Sold | $2.9B |
| Operating Income | $3.4B |
| Selling General And Administrative | $2.3B |
| Research And Development | $686M |
| Operating Expenses | $3B |
| Investment Income Net | - |
| Net Interest Income | -$119M |
| Interest Income | $106M |
| Interest Expense | $242M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $497M |
| Income Before Tax | $3.1B |
| Income Tax Expense | $637M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $2.5B |
| Comprehensive Income Net Of Tax | - |
| Ebit | $3.4B |
| Ebitda | $3.9B |
| Net Income | $2.5B |
| Field | Value (USD) |
|---|---|
| Total Assets | $14B |
| Total Current Assets | $6B |
| Cash And Cash Equivalents At Carrying Value | $2B |
| Cash And Short Term Investments | $2B |
| Inventory | $2.3B |
| Current Net Receivables | $1.3B |
| Total Non Current Assets | $8.3B |
| Property Plant Equipment | $3.6B |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $1.1B |
| Intangible Assets Excluding Goodwill | $1.1B |
| Goodwill | $2.7B |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | $2M |
| Other Current Assets | $379M |
| Other Non Current Assets | - |
| Total Liabilities | $9.5B |
| Total Current Liabilities | $3.4B |
| Current Accounts Payable | $433M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $1.4B |
| Total Non Current Liabilities | $6.1B |
| Capital Lease Obligations | $174M |
| Long Term Debt | $5.2B |
| Current Long Term Debt | $1.4B |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $6.7B |
| Other Current Liabilities | $1.5B |
| Other Non Current Liabilities | $222M |
| Total Shareholder Equity | $4.8B |
| Treasury Stock | - |
| Retained Earnings | $12B |
| Common Stock | $5M |
| Common Stock Shares Outstanding | $455M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | $3B |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $497M |
| Capital Expenditures | $655M |
| Change In Receivables | - |
| Change In Inventory | -$40M |
| Profit Loss | - |
| Cashflow From Investment | -$315M |
| Cashflow From Financing | -$2.7B |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | $786M |
| Dividend Payout Common Stock | $786M |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | -$1.9B |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | $2.5B |
| Field | Value (USD) |
|---|---|
| Gross Profit | $6.4B |
| Total Revenue | $9.3B |
| Cost Of Revenue | $2.9B |
| Costof Goods And Services Sold | $2.9B |
| Operating Income | $3.4B |
| Selling General And Administrative | $2.3B |
| Research And Development | $686M |
| Operating Expenses | $3B |
| Investment Income Net | - |
| Net Interest Income | -$119M |
| Interest Income | $106M |
| Interest Expense | $242M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $497M |
| Income Before Tax | $3.1B |
| Income Tax Expense | $637M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $2.5B |
| Comprehensive Income Net Of Tax | - |
| Ebit | $3.4B |
| Ebitda | $3.9B |
| Net Income | $2.5B |
| Field | Value |
|---|---|
| Ex Dividend Date | 2025-10-31 |
| Declaration Date | 2025-10-09 |
| Record Date | 2025-10-31 |
| Payment Date | 2025-12-02 |
| Amount | 0.5 |
Sector: HEALTHCARE
Industry: DRUG MANUFACTURERS - SPECIALTY & GENERIC
Zoetis Inc. (ZTS) is a leading global animal health company dedicated to improving the health and well-being of livestock and companion animals. As the largest manufacturer of medicines and vaccines for animals, Zoetis leverages advanced research and development to offer a comprehensive range of innovative products that enhance productivity in animal agriculture and support the well-being of pets globally. Committed to sustainability and animal welfare, Zoetis is well-positioned to meet the increasing demand for premium animal health solutions in an expanding market, making it an attractive investment opportunity for institutional investors.